159992 创新药
已收盘 12-26 15:00:00
资讯
新帖
简况
每周股票复盘：联环药业（600513）创新药LH-1801预计2026年一季度揭盲
证券之星 · 03:35
每周股票复盘：联环药业（600513）创新药LH-1801预计2026年一季度揭盲
突破创新药研发瓶颈，谁将为人类赢得下一场生命之战？
睿见Economy · 12-26 15:51
突破创新药研发瓶颈，谁将为人类赢得下一场生命之战？
长城基金梁福睿：2026年创新药行情值得期待
新浪基金 · 12-26 14:57
长城基金梁福睿：2026年创新药行情值得期待
优宁维：创新药研发是公司产品主要应用领域之一
证券之星 · 12-24
优宁维：创新药研发是公司产品主要应用领域之一
中国创新药迈入全球化临界点，云顶新耀擘画进阶新篇
21世纪经济报道 · 12-23
中国创新药迈入全球化临界点，云顶新耀擘画进阶新篇
十年深耕：中国创新药授权交易从“爆发”迈向“长红”
21世纪经济报道 · 12-23
十年深耕：中国创新药授权交易从“爆发”迈向“长红”
聚焦肺癌围术期免疫治疗新发展，让高品质创新药惠及更多患者
上观新闻 · 12-23
聚焦肺癌围术期免疫治疗新发展，让高品质创新药惠及更多患者
创新药板块的强心剂! 富国银行押注Arcellx(ACLX.US)重塑骨髓瘤治疗格局 预言股价将涨超50%
智通财经 · 12-23
创新药板块的强心剂! 富国银行押注Arcellx(ACLX.US)重塑骨髓瘤治疗格局 预言股价将涨超50%
信达生物“染蓝”：中国创新药从故事到资产的成人礼
21世纪经济报道 · 12-23
信达生物“染蓝”：中国创新药从故事到资产的成人礼
沙利文毛化：中国创新药2026年迎升浪，加速国际化价值兑现
21世纪经济报道 · 12-22
沙利文毛化：中国创新药2026年迎升浪，加速国际化价值兑现
海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理
智通财经 · 12-22
海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理
石药集团CEO换帅：蔡磊接棒，剑指创新药全球化
21世纪经济报道 · 12-22
石药集团CEO换帅：蔡磊接棒，剑指创新药全球化
高特佳于建林：锚定下一代疗法，创新药行业走向价值深化
21世纪经济报道 · 12-22
高特佳于建林：锚定下一代疗法，创新药行业走向价值深化
三连涨后首度回调，港股通创新药ETF（520880）跌近1%高频溢价！机构：关注“硬创新”+“强出海”创新药资产
新浪基金 · 12-22
三连涨后首度回调，港股通创新药ETF（520880）跌近1%高频溢价！机构：关注“硬创新”+“强出海”创新药资产
千亿美元交易引爆全球：2025年中国创新药出海的飞跃时刻
华夏时报网 · 12-22
千亿美元交易引爆全球：2025年中国创新药出海的飞跃时刻
瑞博生物通过聆讯：强大技术壁垒叠加专而精管线，港市再迎稀缺创新药标的
智通财经网 · 12-21
瑞博生物通过聆讯：强大技术壁垒叠加专而精管线，港市再迎稀缺创新药标的
创新药、新能源车等全线拉升
中国基金报 · 12-19
创新药、新能源车等全线拉升
招商证券：医药板块创新药产业链仍是主线 重点关注小核酸等技术方向
智通财经 · 12-19
招商证券：医药板块创新药产业链仍是主线 重点关注小核酸等技术方向
九典制药：正在全面转型创新药研发，迅速布局创新药
第一财经 · 12-18
九典制药：正在全面转型创新药研发，迅速布局创新药
奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察
华夏时报网 · 12-18
奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.854,"timestamp":1766732580000,"preClose":0.856,"halted":0,"volume":386925099,"delay":0,"changeRate":-0.0023,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.002,"latestTime":"12-26 15:00:00","open":0.854,"high":0.857,"low":0.849,"amount":330000000,"amplitude":0.0093,"askPrice":0.855,"askSize":46469,"bidPrice":0.854,"bidSize":13881,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":5,"adr":0,"adjPreClose":0.856,"symbolType":"fund","openAndCloseTimeList":[[1766712600000,1766719800000],[1766725200000,1766732400000]],"highLimit":0.942,"lowLimit":0.77,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.548028,"marketValue":0,"turnoverRate":0,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-29。","floatMarketCap":0},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2594326242","title":"每周股票复盘：联环药业（600513）创新药LH-1801预计2026年一季度揭盲","url":"https://stock-news.laohu8.com/highlight/detail?id=2594326242","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594326242?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:35","pubTimestamp":1766864112,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，联环药业报收于18.3元，较上周的17.98元上涨1.78%。本周，联环药业12月26日盘中最高价报18.48元。联环药业于2025年12月22日召开2025年第三季度业绩说明会，管理层回应投资者关切，表示持续推进呼吸系统、肿瘤、内分泌等领域创新药研发，多个项目处于临床阶段，其中LH-1801预计2026年一季度揭盲。创新药LH-1801处于III期临床52周随访阶段，预计2026年一季度揭盲。该药品用于治疗成人原发性高血压，2024年度全国样本医院销售额为5,873.19万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239","06978","159992","BK1574","BK1161"],"gpt_icon":0},{"id":"2594262003","title":"突破创新药研发瓶颈，谁将为人类赢得下一场生命之战？","url":"https://stock-news.laohu8.com/highlight/detail?id=2594262003","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594262003?lang=zh_cn&edition=full","pubTime":"2025-12-26 15:51","pubTimestamp":1766735460,"startTime":"0","endTime":"0","summary":" “为中国经济点赞——企业家之夜”已于12月17日正式启动，目前点赞活动正在火热进行中。 在科技飞速发展的当下，创新药研发作为生命科学领域的关键战场，承载着人类对抗疾病、追求健康的美好愿景。药明康德董事长李革、江苏恒瑞医药董事长孙飘扬、康方生物主席夏瑜、百利天恒药业董事长朱义，谁将为人类赢得下一场生命之战？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-26/doc-inhecipr0850194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","06978"],"gpt_icon":0},{"id":"2594193261","title":"长城基金梁福睿：2026年创新药行情值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2594193261","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594193261?lang=zh_cn&edition=full","pubTime":"2025-12-26 14:57","pubTimestamp":1766732220,"startTime":"0","endTime":"0","summary":"近日，长城基金举办了2026年度投资策略会，长城医药产业基金经理梁福睿在会上就创新药领域的热门问题展开了深度探讨。 展望2026年，梁福睿依旧看好创新药行情。梁福睿认为，2026年创新药有望兼具Beta和Alpha，是双层共振的方向。叠加2026年全球流动性环境可能总体宽裕，以及自身产业趋势加持、Alpha变化支撑，明年创新药值得期待。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-26/doc-inheccft0928983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","BK1161","06978"],"gpt_icon":0},{"id":"2593422894","title":"优宁维：创新药研发是公司产品主要应用领域之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2593422894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593422894?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:05","pubTimestamp":1766559928,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：祁总，公司有没有向创新药或者脑机接口进军布局？优宁维回复：投资者您好，公司主要面向国内高等院校、科研院所、医院和生物医药企业等科研端，提供生命科学试剂、设备、耗材、综合技术服务等产品和服务。创新药研发是公司产品的主要应用领域之一。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","06978","301166","159992","BK0250"],"gpt_icon":0},{"id":"2593556495","title":"中国创新药迈入全球化临界点，云顶新耀擘画进阶新篇","url":"https://stock-news.laohu8.com/highlight/detail?id=2593556495","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593556495?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:16","pubTimestamp":1766481360,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者 韩利明2025年，中国创新药行业的成绩单已跃然纸上：生物医药市场规模居全球第二，在研创新药约占全球比重达30%；创新资产的全球吸引力持续攀升，截至11月18日，国产创新 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251223/c673440107.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251223/c673440107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2593498324","title":"十年深耕：中国创新药授权交易从“爆发”迈向“长红”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593498324","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593498324?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:24","pubTimestamp":1766478262,"startTime":"0","endTime":"0","summary":"BD（商务拓展），曾在生物医药领域融资市场持续收紧的“资本寒冬”中，为中国生物科技公司（Biotech）带来了新的募资契机。2025年，BD掀起了前所未有的热潮。央视财经数据显示，截至2025年11月18日，国产创新药对外授权总金额已突破千亿美元，相较于2024年实现了翻倍式增长。手握优质BD项目的Biotech迎来了股价上涨、IPO畅通等红利，更有不少企业提前预告BD进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233599517231.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599517231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2593245462","title":"聚焦肺癌围术期免疫治疗新发展，让高品质创新药惠及更多患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2593245462","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593245462?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:21","pubTimestamp":1766474482,"startTime":"0","endTime":"0","summary":"由北京中西医慢病防治促进会发起、百济神州支持的肺癌围术期全程管理规范化诊疗学术交流会日前举行。来自全国的肺癌专家齐聚一堂，共同讨论肺癌围术期免疫治疗最新研究成果及临床经验，推动肺癌免疫治疗的规范化、精准化发展，为患者提供更为科学、有效的治疗方案，最终提升我国肺癌治疗的整体水平与国际竞争力。肺癌是我国发病率与死亡率最高的恶性肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599448769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","BK1161","BK1574"],"gpt_icon":0},{"id":"2593462595","title":"创新药板块的强心剂! 富国银行押注Arcellx(ACLX.US)重塑骨髓瘤治疗格局 预言股价将涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593462595","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593462595?lang=zh_cn&edition=full","pubTime":"2025-12-23 14:58","pubTimestamp":1766473090,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华尔街金融巨头富国银行对于美国生物科技新生代势力Arcellx启动评级与目标价覆盖并给予“增持”评级，称其用于多发性骨髓瘤的试验性CAR-T疗法“anito-cel”，是这种血液癌症管理系统中的“未来支柱”，未来将彻底重塑骨髓瘤治疗格局。今年以来Arcellx股价表现不佳，年内迄今跌超15%，大幅跑输标普500指数。在富国银行等知名卖方机构的分析师们看来，anito-cel有望彻底颠覆现有的多发性骨髓瘤治疗市场格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1363072403.SGD","LU0048573561.USD","BK4559","LU1506573853.SGD","LU1267930227.SGD","LU0106831901.USD","LU0417517546.SGD","LU1814569148.SGD","BK4504","IE0002270589.USD","LU1668664300.SGD","IE000M9KFDE8.USD","LU0211328371.USD","LU0942090050.USD","LU2236285917.USD","BK4139","LU2361045086.USD","LU1267930490.SGD","LU2361044949.HKD","LU0251142724.SGD","LU1074936037.SGD","LU0640476718.USD","IE00B7SZLL34.SGD","LU0149725797.USD","LU0289960550.SGD","LU0314106906.USD","BK1161","06978","LU0128525929.USD","LU1035773651.USD","159992","LU0868494617.USD","LU2461242641.AUD","LU0648001328.SGD","LU0787776722.HKD","LU0128525689.USD","ACLX","LU0130102774.USD","BK4207","LU0154236417.USD","LU0310800379.SGD","LU0130517989.USD","LU0971096721.USD","LU0477156953.USD","LU0175139822.USD","LU1069347547.HKD","LU0868494708.USD","LU0683600562.USD","BK1574","LU1791807156.HKD"],"gpt_icon":0},{"id":"2593045079","title":"信达生物“染蓝”：中国创新药从故事到资产的成人礼","url":"https://stock-news.laohu8.com/highlight/detail?id=2593045079","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593045079?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:33","pubTimestamp":1766457227,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛资本市场对于中国创新药的态度，在过去的几年间经历了剧烈的摇摆。在行业高歌猛进时，biotech往往被描绘为前景无限的未来之星；而当周期下行时，它们又被打上“高风险、不确定性”的标签。恒生指数的选择标准——市场规模、流动性及财务稳定性，直指投资逻辑的核心。这些传统的价值标尺与过往专注于“讲故事”的biotech企业估值体系形成了鲜明对比。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233599280151.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599280151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU2097828714.EUR","06978","LU2097828631.EUR","BK1574","LU2097828474.EUR","LU2097828557.USD","159992","LU0502904849.HKD","01801","HK0000165453.HKD","BK1161","LU2488822045.USD","LU2242644610.SGD","LU2097828805.USD","LU2328871848.SGD","LU1969619763.USD","LU0455707207.USD","BK1589"],"gpt_icon":0},{"id":"2593148175","title":"沙利文毛化：中国创新药2026年迎升浪，加速国际化价值兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2593148175","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593148175?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:16","pubTimestamp":1766402190,"startTime":"0","endTime":"0","summary":"近一年来，中国药企在国际舞台上频频亮相，国际社会对中国制药业的发展关注度持续攀升。正如《经济学人》所指出的：中国创新药正处于全球化的临界点。从中国临床试验的参与度到对外授权许可的规模，中国药企在全球市场的占比均显著提升；过去一年，中国生物科技企业的股价涨幅远超美国同类企业，这一切无不表明，全球生物医药创新长达一个世纪的“西方主导”格局正悄然改变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512223598433738.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598433738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2593485369","title":"海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485369","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485369?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:36","pubTimestamp":1766396197,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司子公司辽宁海思科制药有限公司于近日收到国家药品监督管理局下发的《受理通书》，涉及药品：“HSK46575”。本次获得受理的为本品联合奥拉帕利片或联合多西他赛和泼尼松片用于前列腺癌的治疗适应症的临床试验申请。HSK46575片是公司自主研发的一种口服、强效和高选择性的小分子抑制剂，拟用于前列腺癌的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK1161","002653","BK1574","BK0188","159992","BK0033","BK0028","BK0239","IND","06978"],"gpt_icon":0},{"id":"2593483853","title":"石药集团CEO换帅：蔡磊接棒，剑指创新药全球化","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483853","media":"21世纪经济报道","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483853?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:06","pubTimestamp":1766394360,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者闫硕12月19日，石药集团(01093.HK)发布公告披露多个核心岗位人事调整，引发行业广泛关注。公告显示，张翠龙因工作调动不再担任董事会副主席、首席执行官及授权代表，但仍 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://news.10jqka.com.cn/20251222/c673401654.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20251222/c673401654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2593102524","title":"高特佳于建林：锚定下一代疗法，创新药行业走向价值深化","url":"https://stock-news.laohu8.com/highlight/detail?id=2593102524","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593102524?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:43","pubTimestamp":1766389389,"startTime":"0","endTime":"0","summary":"随着我国生物医药产业竞争力与创新活力持续攀升，2025创新药高质量发展大会上国家医保局披露最新数据显示，年内中国批准上市的创新药已达69个，超过去年全年的48个，再次创下历史新高。当前，中国医药产业规模已位居全球第二，创新药在研数目约占全球的30%。这一高质量发展态势的背后，离不开政策的持续赋能，也得益于我国创新药企的深耕加码。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512223598279916.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598279916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","BK1574","BK1161"],"gpt_icon":0},{"id":"2593530101","title":"三连涨后首度回调，港股通创新药ETF（520880）跌近1%高频溢价！机构：关注“硬创新”+“强出海”创新药资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2593530101","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593530101?lang=zh_cn&edition=full","pubTime":"2025-12-22 14:45","pubTimestamp":1766385900,"startTime":"0","endTime":"0","summary":"12月22日，港股通创新药板块三连涨后首度回调，高人气港股通创新药ETF午后一度跌近1%，场内再现高频溢价，显示买盘资金较为活跃。未来，应关注部分优质创新药资产，一是“硬创新”资产，二是具备较强出海潜力的资产。 把握创新药低吸窗口期，首选同类最大港股通创新药ETF及其场外联接基金，标的指数恒生港股通创新药精选指数具备三大独特优势：","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-22/doc-inhcsexm7825049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","520880","159992","BK1574"],"gpt_icon":0},{"id":"2593101186","title":"千亿美元交易引爆全球：2025年中国创新药出海的飞跃时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2593101186","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593101186?lang=zh_cn&edition=full","pubTime":"2025-12-22 14:43","pubTimestamp":1766385783,"startTime":"0","endTime":"0","summary":"2025年，中国创新药产业站在了全球医药创新版图的重要位置。这一年，对外授权（BD）交易总额历史性突破1000亿美元，百亿美元级超级订单密集落地；合作模式从“卖青苗”式的一次性出售，升级为“成本共担、利益共享”的尝试；研发管线结构显著优化——非肿瘤研发管线占比逼近肿瘤管线，自免、代谢、中枢神经、纤维化、抗感染等新兴赛道成为增长主力；资本市场同步强势反弹，政策支持体系持续完善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512223598230937.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598230937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","BK1574","159992"],"gpt_icon":0},{"id":"2593276791","title":"瑞博生物通过聆讯：强大技术壁垒叠加专而精管线，港市再迎稀缺创新药标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2593276791","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593276791?lang=zh_cn&edition=full","pubTime":"2025-12-21 22:25","pubTimestamp":1766327159,"startTime":"0","endTime":"0","summary":"随着中国小核酸药物主要开拓者——瑞博生物通过港交所聆讯，港股市场又增添了一家极具稀缺价值的创新药标的。故此，国内如瑞博生物这样能够突破行业技术壁垒并接近商业化前夕的创新药企可谓凤毛麟角。据悉，瑞博生物是全球为数不多拥有自主研发且经过临床验证的GalNAc递送技术的企业之一，该技术基于对siRNA药物特异性递送，增强了疗效和改善了安全性，正在颠覆创新药物的治疗理念。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06978","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2592955166","title":"创新药、新能源车等全线拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2592955166","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592955166?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:51","pubTimestamp":1766141516,"startTime":"0","endTime":"0","summary":"【导读】港股三大指数集体收涨12月19日，港股三大指数高开高走，截至收盘，恒生指数上涨0.75%，恒生科技指数上涨1.12%，恒生国企指数上涨0.68%。创新药、新能源汽车等涨幅靠前具体来看，当日权重科技股集体上涨，腾讯、快手、网易、美团、百度均涨超1%。板块方面，当日创新药概念股涨幅靠前，其中，映恩生物涨幅达9.29%，药明生物涨幅达4.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512193596898585.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596898585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159992","BK1161","399417","161028","06978"],"gpt_icon":0},{"id":"2592131496","title":"招商证券：医药板块创新药产业链仍是主线 重点关注小核酸等技术方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2592131496","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592131496?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:17","pubTimestamp":1766110668,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券发布研报称，2026年医药板块在创新出海持续兑现、医疗内需分化的产业趋势下，有望出现结构行情。创新药产业链仍是主线，除观察二代IO、减重、ADC板块的临床数据外，尤其关注小核酸技术方向的加速发展；同时关注CXO、上游、原料药中具备景气度与业绩兑现的公司。创新及药品产业链CXO：在2025年以来，外需CXO业绩逐步兑现，分子类型持续革新带来新的产业机会；内需CRO需求结构性改善，新签订单持续增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","159938","BK0028","BK0183","BK1515","BK1574","159992","BK0276","BK0188","BK1564","BK0012","06978","BK0010","600999","06099","09939","BK1161"],"gpt_icon":0},{"id":"2592902107","title":"九典制药：正在全面转型创新药研发，迅速布局创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902107","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592902107?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:13","pubTimestamp":1766067180,"startTime":"0","endTime":"0","summary":"九典制药在机构调研时表示，公司目前正在全面转型创新药研发，采用“多个研发中心+多种药物形式+多种合作模式”策略迅速布局创新药。(本文来自第一财经)\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfvmf2970774.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfvmf2970774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK1161","BK1574","06978","159992","300705"],"gpt_icon":0},{"id":"2592201369","title":"奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2592201369","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592201369?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:03","pubTimestamp":1766041380,"startTime":"0","endTime":"0","summary":"12月15日，生物医药公司诺诚健华宣布，其核心产品奥布替尼用于治疗系统性红斑狼疮（SLE）的IIb期临床研究达到主要终点，并已获国家药品监督管理局批准开展Ⅲ期临床试验。这一进展虽标志着该药在开拓自身免疫疾病这一巨大新市场的道路上迈出关键一步，但其通往成功商业化的道路仍布满不确定性，或将面临来自临床试验、市场竞争及公司战略的多重严峻挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512183595356395.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595356395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0239","BK1161","BK4077","06978","SLE","688428","09969","159992"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766923397430,"stockEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":-0.0328},{"period":"3month","weight":-0.0973},{"period":"6month","weight":0.0921},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.2253}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}